Outcome
Type |
Measure |
Description |
Time frame |
Safety issue |
Other |
Height (Anthropometrics Data) |
Patient height measured in meters (m) |
Baseline |
|
Other |
Weight (Anthropometrics Data) |
Patient's body weight in kilograms (kg) |
Baseline |
|
Other |
Body Mass Index (Anthropometrics Data) |
Weight and height will be combined to report body mass index in kg/m^2 |
Baseline |
|
Other |
Demographics Data |
Registration of information provided by the patient on sex, age, education level. occupation and civil status |
Baseline |
|
Primary |
FIQ (Fibromyalgia Impact Questionnaire) |
Evaluates the impact of fibromyalgia on the patient's quality of life.The total score of the FIQ is from 0 to 100. A higher score means a greater impact of the disease on the patient. |
Baseline |
|
Primary |
FIQ (Fibromyalgia Impact Questionnaire) |
Evaluates the impact of fibromyalgia on the patient's quality of life.The total score of the FIQ is from 0 to 100. A higher score means a greater impact of the disease on the patient. |
at eight weeks |
|
Primary |
FIQ (Fibromyalgia Impact Questionnaire) |
Evaluates the impact of fibromyalgia on the patient's quality of life.The total score of the FIQ is from 0 to 100. A higher score means a greater impact of the disease on the patient. |
at twelve weeks |
|
Primary |
ABC-16 (Activities-specific Balance Confidence scale-16 items) |
Evaluates the balance confidence in performing activities of daily living. The total score of the ABC-16 is from 0% to 100%, with higher values associated with higher balance confidence. |
Baseline |
|
Primary |
ABC-16 (Activities-specific Balance Confidence scale-16 items) |
Evaluates the balance confidence in performing activities of daily living. The total score of the ABC-16 is from 0% to 100%, with higher values associated with higher balance confidence. |
at eight weeks |
|
Primary |
ABC-16 (Activities-specific Balance Confidence scale-16 items) |
Evaluates the balance confidence in performing activities of daily living. The total score of the ABC-16 is from 0% to 100%, with higher values associated with higher balance confidence. |
at twelve weeks |
|
Primary |
DHI (Dizziness Handicap Inventory) |
Evaluates the level of disability related to the impact of dizziness on daily function and quality of life. The total score of the DHI is from 0 to100 points. A higher score indicates a greater degree of disability due to the vertiginous symptoms. |
Baseline |
|
Primary |
DHI (Dizziness Handicap Inventory) |
Evaluates the level of disability related to the impact of dizziness on daily function and quality of life. The total score of the DHI is from 0 to100 points. A higher score indicates a greater degree of disability due to the vertiginous symptoms. |
at eight weeks |
|
Primary |
DHI (Dizziness Handicap Inventory) |
Evaluates the level of disability related to the impact of dizziness on daily function and quality of life. The total score of the DHI is from 0 to100 points. A higher score indicates a greater degree of disability due to the vertiginous symptoms. |
at twelve weeks. |
|
Secondary |
CSI (Central Sensitization Inventory) |
Evaluates a wide range of somatic and emotional symptoms common to central sensitization syndromes (CSS). The total score of the CSI from 0 to 100. Higher scores indicate greater severity of symptoms. |
Baseline |
|
Secondary |
CSI (Central Sensitization Inventory) |
Evaluates a wide range of somatic and emotional symptoms common to central sensitization syndromes (CSS). The total score of the CSI from 0 to 100. Higher scores indicate greater severity of symptoms. |
at eight weeks |
|
Secondary |
CSI (Central Sensitization Inventory) |
Evaluates a wide range of somatic and emotional symptoms common to central sensitization syndromes (CSS). The total score of the CSI from 0 to 100. Higher scores indicate greater severity of symptoms. |
at twelve weeks. |
|
Secondary |
PCS (Pain Catastrophizing Scale) |
Evaluates the patient's catastrophic thoughts. The total score of the PCS from 0 to 52. Higher scores indicate a greater presence of catastrophic thoughts. |
Baseline |
|
Secondary |
PCS (Pain Catastrophizing Scale) |
Evaluates the patient's catastrophic thoughts. The total score of the PCS from 0 to 52. Higher scores indicate a greater presence of catastrophic thoughts. |
at eight weeks |
|
Secondary |
PCS (Pain Catastrophizing Scale) |
Evaluates the patient's catastrophic thoughts. The total score of the PCS from 0 to 52. Higher scores indicate a greater presence of catastrophic thoughts. |
at twelve weeks. |
|
Secondary |
TSK (Tampa Scale for Kinesiophobia) |
Evaluates fear of movement to injury. The total score of the TSK from 11 to 44 points. Higher scores indicate a greater fear of movement. |
Baseline |
|
Secondary |
TSK (Tampa Scale for Kinesiophobia) |
Evaluates fear of movement to injury. The total score of the TSK from 11 to 44 points. Higher scores indicate a greater fear of movement. |
at eight weeks |
|
Secondary |
TSK (Tampa Scale for Kinesiophobia) |
Evaluates fear of movement to injury. The total score of the TSK from 11 to 44 points. Higher scores indicate a greater fear of movement. |
at twelve weeks. |
|
Secondary |
VAS-pain (Visual Analogue Scale) |
Evaluates the pain on a numerical scale from 0 to 10. Higher scores indicate more pain |
Baseline |
|
Secondary |
VAS-pain (Visual Analogue Scale) |
Evaluates the pain on a numerical scale from 0 to 10. Higher scores indicate more pain |
at eight weeks |
|
Secondary |
VAS-pain (Visual Analogue Scale) |
Evaluates the pain on a numerical scale from 0 to 10. Higher scores indicate more pain |
at twelve weeks |
|
Secondary |
SF-12 (12-Item Short Form Survey) |
Evaluates the impact of health on an individual's everyday life. Used as a quality of life measure. |
Baseline |
|
Secondary |
SF-12 (12-Item Short Form Survey) |
Evaluates the impact of health on an individual's everyday life. Used as a quality of life measure. |
at eight weeks |
|
Secondary |
SF-12 (12-Item Short Form Survey) |
Evaluates the impact of health on an individual's everyday life. Used as a quality of life measure. |
at twelve weeks |
|
Secondary |
FES-I (Falls Efficacy Scale-International) |
Evaluates the fear of falling. The total score of the FES-I from 16 to 64 points. Higher scores indicate greater fear of falling. |
Baseline |
|
Secondary |
FES-I (Falls Efficacy Scale-International) |
Evaluates the fear of falling. The total score of the FES-I from 16 to 64 points. Higher scores indicate greater fear of falling. |
at eight weeks |
|
Secondary |
FES-I (Falls Efficacy Scale-International) |
Evaluates the fear of falling. The total score of the FES-I from 16 to 64 points. Higher scores indicate greater fear of falling. |
at twelve weeks |
|
Secondary |
FSS (Fatigue Severity Scale) |
Evaluates severity of fatigue. Higher scores indicate a greater severity of fatigue |
Baseline |
|
Secondary |
FSS (Fatigue Severity Scale) |
Evaluates severity of fatigue. Higher scores indicate a greater severity of fatigue |
at eight weeks |
|
Secondary |
FSS (Fatigue Severity Scale) |
Evaluates severity of fatigue. Higher scores indicate a greater severity of fatigue |
at twelve weeks |
|
Secondary |
20-item JAEN screening tool |
Evaluates balance and neuromotor function in patients with fibromyalgia. Thd total scale of the Jaen-Screening Tools, from 0 to 80 points. A higher score indicates a greater degree of balance disorder. |
Baseline |
|
Secondary |
20-item JAEN screening tool |
Evaluates balance and neuromotor function in patients with fibromyalgia. Thd total scale of the Jaen-Screening Tools, from 0 to 80 points. A higher score indicates a greater degree of balance disorder. |
at eight weeks |
|
Secondary |
20-item JAEN screening tool |
Evaluates balance and neuromotor function in patients with fibromyalgia. Thd total scale of the Jaen-Screening Tools, from 0 to 80 points. A higher score indicates a greater degree of balance disorder. |
at twelve weeks |
|
Secondary |
SVV (Subjective Visual Vertical) |
Evaluates the perception of verticality, measured using the Subjective Visual Vertical (SVV) test using a virtual reality device. |
baseline |
|
Secondary |
SVV (Subjective Visual Vertical) |
Evaluates the perception of verticality, measured using the Subjective Visual Vertical (SVV) test using a virtual reality device. |
at eight weeks |
|
Secondary |
SVV (Subjective Visual Vertical) |
Evaluates the perception of verticality, measured using the Subjective Visual Vertical (SVV) test using a virtual reality device. |
at twelve weeks |
|
Secondary |
Stabilometric Platform |
Instrument composed of resistive pressure sensors, used to measure the static or postural balance. The test was performed under both eyes-open and eyes-closed conditions. |
Baseline |
|
Secondary |
Stabilometric Platform |
Instrument composed of resistive pressure sensors, used to measure the static or postural balance. The test was performed under both eyes-open and eyes-closed conditions. |
at eight weeks |
|
Secondary |
Stabilometric Platform |
Instrument composed of resistive pressure sensors, used to measure the static or postural balance. The test was performed under both eyes-open and eyes-closed conditions. |
at twelve weeks |
|
Secondary |
Therapeutic Adherence at home |
It assesses adherence to home treatment through a weekly record diary, where patients must record the number of times a day they perform the prescribed exercises, with a range of 0 to 80. Higher scores indicate greater adherence to home treatment. A score of 80 indicates 100% adherence. |
Throughout the intervention phase, eight weeks |
|
Secondary |
Satisfaction level |
Evaluates the level of satisfaction using a Likert scale, with five response options, from "very dissatisfied" to "very satisfied". The total score of 0-24. A high score indicates greater satisfaction |
at eight weeks |
|
Secondary |
GRC (Global Change Rating Scales) |
Assesses whether the patient's health status has improved or deteriorated after the treatment received, with ten response options ranging from "the worst it could be" to "the best it could be" |
at eight weeks |
|